Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Intradigm Announces Addition of Samuel Zalipsky to Management Team

Abstract:
Intradigm Corporation, a leading developer of targeted and effective RNA interference (RNAi)
therapeutics, today announced the appointment of Samuel Zalipsky, Ph.D., as vice president, technology development. Dr. Zalipsky brings more than 20 years of experience in the pharmaceutical and biotechnology industry and offers significant expertise in areas critical to Intradigm's growth.

Intradigm Announces Addition of Samuel Zalipsky to Management Team

PALO ALTO, CA | Posted on May 30th, 2007

Dr. Zalipsky comes to Intradigm following an eight-year tenure with
ALZA Corporation, a member of the Johnson & Johnson family of companies,
during which he established himself as a leading expert on drug delivery
systems. His broad drug delivery expertise spans several important areas
including chemistry of peptides, polymers for bio-medical application,
bioconjugates with drugs, peptides/proteins, saccharides, lipids/liposomes,
and nanoparticles. He is widely regarded as an active researcher and
inventor, particularly in the areas of macromolecular and nanoparticular
carrier-mediated delivery.

At ALZA, Dr. Zalipsky established and managed programs focused on
delivery of biopharmaceuticals, PEGylated proteins, and targeted delivery
of liposomes. Prior to his work with ALZA, he held key scientific positions
with SEQUUS Pharmaceuticals and Enzon Inc., while also serving as a
visiting associate professor in the chemistry department of Rutgers
University. In his new role, Dr. Zalipsky will spearhead the continued
development of Intradigm's proprietary nanoparticle-based RNAi delivery
technology, as well as its novel RNAi therapeutic formulations. He will
also be responsible for overseeing the company's work in the areas of new
technology development and new technology in-licensing.

"While Samuel possesses impressive experience in the biotechnology and
pharmaceutical industry, it is the relevance of his expertise as it relates
to Intradigm's RNAi drug delivery focus that makes him such an ideal
addition to our team," said Mohammad Azab, M.D., president and chief
executive officer of Intradigm. "We are very happy to welcome Samuel to
Intradigm and look forward to the critical contributions he will make to
the company and our efforts to bring innovative RNAi therapeutics to the
market."

####

About Intradigm Corporation
Intradigm is a private biotechnology company dedicated to the
development of targeted and effective RNA interference (RNAi) therapeutics
for the treatment of serious diseases with an initial focus on oncology.
The company's expertise in the development and delivery of RNAi molecules
serves as the foundation of Intradigm's drug development platform. In
particular, the company's novel and proprietary RNAi Nanoplex(TM) delivery
technology is unique in its ability to allow the targeted delivery of RNAi
therapeutics to specific tissues though systemic administration.

At present, Intradigm is working to build a high-value internal
pipeline of RNAi oncology therapeutics, and is actively advancing its lead
internal drug candidate, ICS-283, for a variety of cancer indications. The
company is also establishing collaborative relationships with
pharmaceutical and biotechnology companies through which Intradigm's
advanced RNAi delivery technology may be applied to a broad range of therapeutic targets.

For more information, please click here

Contacts:
3350 W Bayshore Rd, Suite 100;
Palo Alto, CA 94303
Phone: (650) 855 9696
Fax: (650) 855 9699

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Laser activated gold pyramids could deliver drugs, DNA into cells without harm: Microstructures create temporary pores in cells March 27th, 2017

Researchers make flexible glass for tiny medical devices: Glass can bend over and over again on a nanoscale March 27th, 2017

Cryo-electron microscopy achieves unprecedented resolution using new computational methods March 25th, 2017

Nanobiotix: The Independent Data Monitoring Committee Recommends the Continuation of the Ongoing Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma March 23rd, 2017

Announcements

Information storage with a nanoscale twist: Discovery of a novel rotational force inside magnetic vortices makes it easier to design ultrahigh capacity disk drives March 28th, 2017

ATTOPSEMI Technology Joins FDXcelerator Program to Deliver Advanced Non-Volatile Memory IP to GLOBALFOUNDRIES 22 FDX Technology Platform: Leading-edge I-fuse brings higher reliability, smaller cell size and ease of programmability for consumer, automotive, and IoT applications March 27th, 2017

Leti and HORIBA Scientific to Host Webinar on Ultrafast Characterization Tool: Plasma Profiling Time-of-Flight Mass Spectrometer Tool Cuts Optimization Time In Layer Deposition and Fabrication of Wide Range of Applications March 27th, 2017

Laser activated gold pyramids could deliver drugs, DNA into cells without harm: Microstructures create temporary pores in cells March 27th, 2017

Appointments/Promotions/New hires/Resignations/Deaths

Francis Alexander Named Deputy Director of Brookhaven Lab's Computational Science Initiative February 16th, 2017

Nanobiotix appoints senior executive from pharmaceutical industry, as Chief Operating Officer: Oncology industry veteran to oversee operations and product commercialization February 8th, 2017

Dr Barbara Armbruster promoted to Worldwide Sales and Marketing Director for XEI Scientific September 27th, 2016

Dr Barbara Armbruster joins XEI Scientific as Marketing Director June 1st, 2016

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project